Recombinant human VASH1
Vasohibin; KIAA1036; VASH; VASH; VASH1; VASH1_HUMAN; Vasohibin1; Vasohibin-1
應用:SDS-PAGE,Western blot,ELISA
Biological activity,immunology research
保存:-20℃
保質期:1年
VASH1 is a angiogenesis inhibitor. It inhibits migration, proliferation and network formation by endothelial cells as well as angiogenesis. This inhibitory effect is selective to endothelial cells as it does not affect the migration of smooth muscle cells or fibroblasts. It does not affect the proliferation of cancer cells in vitro, but inhibits tumor growth and tumor angiogenesis and acts in an autocrine manner. VASH1 also inhibits artery neointimal formation and macrophage infiltration and exhibits heparin-binding activity. There are two named isoforms.
產品名稱:Rabbit Anti-VASH1 antibody
Rabbit Anti-VASH1
別名:Vasohibin; KIAA1036; VASH; VASH; VASH1; VASH1_HUMAN; Vasohibin1; Vasohibin-1
反應:Human,Rat (predicted: Mouse,Rabbit,Pig,Cow,Dog,Horse)
免疫原:KLH conjugated synthetic peptide derived from human VASH1
保存:-20℃
保質期:1年
單克隆抗體
產品名稱:Anti-VASH1 antibody
Mouse Anti-VASH1
別名:Vasohibin; KIAA1036; VASH; VASH; VASH1; VASH1_HUMAN; Vasohibin1; Vasohibin-1
免疫原:KLH conjugated synthetic peptide derived from human VASH1
保存:-20℃
保質期:1年
VASH1 is a angiogenesis inhibitor. It inhibits migration, proliferation and network formation by endothelial cells as well as angiogenesis. This inhibitory effect is selective to endothelial cells as it does not affect the migration of smooth muscle cells or fibroblasts. It does not affect the proliferation of cancer cells in vitro, but inhibits tumor growth and tumor angiogenesis and acts in an autocrine manner. VASH1 also inhibits artery neointimal formation and macrophage infiltration and exhibits heparin-binding activity. There are two named isoforms.
免責聲明
- 凡本網注明“來源:化工儀器網”的所有作品,均為浙江興旺寶明通網絡有限公司-化工儀器網合法擁有版權或有權使用的作品,未經本網授權不得轉載、摘編或利用其它方式使用上述作品。已經本網授權使用作品的,應在授權范圍內使用,并注明“來源:化工儀器網”。違反上述聲明者,本網將追究其相關法律責任。
- 本網轉載并注明自其他來源(非化工儀器網)的作品,目的在于傳遞更多信息,并不代表本網贊同其觀點和對其真實性負責,不承擔此類作品侵權行為的直接責任及連帶責任。其他媒體、網站或個人從本網轉載時,必須保留本網注明的作品第一來源,并自負版權等法律責任。
- 如涉及作品內容、版權等問題,請在作品發表之日起一周內與本網聯系,否則視為放棄相關權利。